Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Twilio Inc (TWLO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Twilio Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Twilio Inc trades at $215 (market cap $32.56B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Twilio Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | TWLO | |
|---|---|---|
Market Cap | $39.89B | $32.56B |
Sector | Health | Technology |
52-Week High | $491.22 | $236.64 |
52-Week Low | $278.09 | $92.44 |
Enterprise Value | $38.15B | $31.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Twilio trades at $214.56, down 1.85% on the day, with a bullish technical outlook from moving averages but overbought RSI signals. The company shows improving fundamentals with revenue growth to $5.07B in 2025 and a return to net profitability. Recent earnings beats and positive analyst sentiment, including a Goldman Sachs buy initiation at $300 (June 24, 2026), highlight momentum in AI-driven cloud communications.
Outlook remains positive given strong earnings beats and margin expansion potential, but high valuation multiples (P/E 325.09) pose risks if growth slows. Investors face execution risks in competitive SaaS markets and sensitivity to tech sector volatility. Wall Street consensus is bullish with 75% buy ratings and a $215.14 price target, near current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Twilio Inc
Twilio Inc. is a cloud-based communication platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces, or APIs, and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
Read more on TWLO →
